Shandong Xinhua Pharmaceutical Co., Ltd. (HKEX: 00719) saw its share price increase by more than 4%. At the time of writing, the stock was up 3.79% to HK$6.02, with a turnover of HK$9.99 million.

Kexing Biopharm Co.,Ltd. announced via its official social media account that it has once again partnered with Shandong Xinhua Pharmaceutical Co., Ltd. (referred to as "Xinhua Pharmaceutical") to export Ethyl Icosapentate soft capsules to Saudi Arabia and the United Arab Emirates.

This collaboration marks another significant partnership between the two companies following their work on Sevelamer Carbonate tablets, jointly aiming to introduce domestically produced high-purity EPA formulations into two major core pharmaceutical markets in the Middle East.

Xinhua Pharmaceutical's Ethyl Icosapentate soft capsules received a Drug Registration Certificate from the National Medical Products Administration in June 2025, achieving full-chain independent control from raw materials to finished formulations for the domestic EPA product.

Currently, a registration application for this drug has been submitted to the U.S. Food and Drug Administration (FDA).